Poolbeg Pharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Poolbeg Pharma ha aumentado sus beneficios a una tasa media anual de 10.5%, mientras que la industria Pharmaceuticals ha visto sus beneficios disminuir en un 5.2% anualmente.

Información clave

10.5%

Tasa de crecimiento de los beneficios

10.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	14.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera	-35.2%
Margen neto	n/a
Última actualización de beneficios	30 Jun 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12

Desglose de ingresos y gastos

Cómo gana y gasta dinero Poolbeg Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

AIM:POLB Ingresos, gastos y beneficios (GBP Millions)
Fecha	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 24	-4	4	2
31 Mar 24	-4	4	2
31 Dec 23	-4	3	2
30 Sep 23	-4	3	2
30 Jun 23	-5	3	2
31 Mar 23	-5	3	2
31 Dec 22	-5	3	2

Ingresos de calidad: POLB actualmente no es rentable.

Margen de beneficios creciente: POLB actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: No hay datos suficientes para determinar si la tasa de crecimiento año a año de los beneficios de POLB ha sido positiva en los últimos 5 años.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de POLB en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: POLB no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (10.2%).

Rentabilidad financiera

Alta ROE: POLB tiene una rentabilidad financiera negativa (-35.17%), ya que actualmente no es rentable.

Poolbeg Pharma Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

Recent updates

Poolbeg Pharma plc Announces U.S. Patent Office Grants U.S. Immunomodulator I Patent

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

New minor risk - Financial data availability

Executive Chairman of The Board recently bought UK£97k worth of stock

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully

Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Poolbeg Pharma Receives Notice of Allowance from the Japanese Patent Office in Relation to its Immunomodulator I Patent Application

Poolbeg Pharma plc Announces Immunomodulator I Patent Opposition Withdrawal

New minor risk - Share price stability

Poolbeg Pharma plc Announces Significant Breakthrough in Its World First Influenza Artificial Intelligence Programme with Cytoreason

Less than half of directors are independent

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Board Changes

Poolbeg Pharma plc Announces Strategic Expansion of Polb 001 into Oncology

Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial

Poolbeg Pharma Identifies Novel RSV Drug Candidates

Poolbeg Pharma plc Announces POLB 001 LPS Human Challenge Clinical Trial Successfully Completed

Poolbeg Pharma Announces Completion of Influenza AI Model Build

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma plc Receives Ethics and Competent Authority Approval to Commence Its Lipopolysaccharide (Lps) Human Challenge Clinical Trial for Polb 00

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Poolbeg Pharma plc Provides Project Update for AI Model of RSV Data

Poolbeg Pharma PLC Provides Update on POLB 001 Clinical Development

No independent directors

Poolbeg Pharma plc Provides an Update on the Strengthening of Its Intellectual Property for Its Asset POLB 002

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

Poolbeg Pharma PLC has completed an IPO in the amount of £25 million.

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado